Thorax

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
[Advanced]

Published Online First: 15 June 2007. doi:10.1136/thx.2007.078915
Thorax 2008;63:49-52
Copyright © 2008 BMJ Publishing Group Ltd & British Thoracic Society

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow web only appendices
Right arrow All Versions of this Article:
thx.2007.078915v1
63/1/49    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Add article to my folders
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nouraei, S A R
Right arrow Articles by Sandhu, G S
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nouraei, S A R
Right arrow Articles by Sandhu, G S

AIRWAY PATHOLOGY

Results of endoscopic surgery and intralesional steroid therapy for airway compromise due to tracheobronchial Wegener’s granulomatosis

S A R Nouraei1, R Obholzer1, P W Ind2, A D Salama3, C D Pusey3, F Porter4, D J Howard1, G S Sandhu1

1 Department of Ear Nose and Throat Surgery, Charing Cross Hospital, London, UK
2 Department of Respiratory Medicine, Hammersmith Hospital, London, UK
3 Department of Renal Medicine, Hammersmith Hospital, London, UK
4 Department of Anaesthesia, Charing Cross Hospital, London, UK

Correspondence to:
Dr Reza Nouraei, National Centre for Airway Reconstruction, Department of Ear Nose and Throat Surgery, Charing Cross Hospital, London W6 8RF, UK; RN{at}cantab.net

Background: Upper airway compromise due to tracheobronchial stenosis commonly occurs in patients with Wegener’s granulomatosis (WG). There is at present no consensus on the optimal management of this life threatening condition.

Objective: To assess the results of laryngo-tracheo-bronchoscopy, intralesional steroid therapy, laser surgery and dilatation in managing obstructive tracheobronchial WG.

Methods: Records of 18 previously untreated stridulous patients with obstructive tracheobronchial WG, treated between 2004 and 2006, were prospectively recorded on an airway database and retrospectively reviewed. Information about patient and lesion characteristics and treatment details were recorded. Treatment progress was illustrated using a timeline plot, and intervention-free intervals were calculated with actuarial analysis.

Results: There were nine males and the average age at presentation was 40 (16) years (range 13–74). There were 13 patients with tracheal and five with tracheal and bronchial lesions. The average tracheal lesion height was 8 (3) mm, located 23 (9) mm below the glottis. There were 1, 10 and 7 Myer-Cotton grade I, II and III lesions, respectively. Mean intervention-free interval following minimally invasive treatment was 26 (2.8) months. Following endobronchial therapy, the median intervention-free interval was 22 months (p>0.8 vs tracheal lesions). No patient required a tracheostomy or endoluminal stenting.

Conclusions: Intralesional steroid therapy and conservative endoluminal surgery is an effective strategy for treating airway compromise due to active tracheal and bronchial WG, obviating the need for airway bypass or stenting. We recommend the combination of endotracheal dilatation, conservative laser surgery and steroid therapy as the standard of care for treating airway compromise due to obstructive tracheobronchial WG.








HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER
Terms and conditions relating to subscriptions purchased online  ¦  Website terms and conditions  ¦  Privacy policy
Copyright © 2008 BMJ Publishing Group Ltd & British Thoracic Society